What Bezastad Retard Treats: Main Uses and Benefits

Bezastad retard is applied in addressing symptoms related to physical discomfort. It is generally used in areas where short-term symptom management is appropriate and contributes to easing the overall symptom load. This medication is commonly used to help manage symptoms related to heightened physiological activity and symptoms that create noticeable physiological strain.

Quick Fact: Relief for Acute Discomfort

This medicine is considered relevant for easing symptom clusters that may become intense or disruptive, such as those associated with acute or episodic changes. It provides supportive relief when symptoms interfere with routine activities, supporting patients during episodes of increased discomfort or tension. It is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability.

Therapeutic Uses at a Glance

Bezastad retard is applied in clinical settings that involve acute or unstable symptom patterns, often used when symptoms intensify and supportive relief is needed, and is relevant for easing symptoms related to inflammatory or irritative states. It helps maintain a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases.

Regulatory References

1. U.S. Food and Drug Administration (FDA) DailyMed Overview

Eligibility for Bezastad Retard (Bezafibrate 400 mg Sustained-Release)

The official regulatory labeling for Bezastad retard strictly defines who can and cannot use this sustained-release formulation, with non-eligibility often determined by organ function and pre-existing conditions.

---

Category	Official Regulatory Status
Adult Use	Approved for adult patients with specific types of hyperlipidaemia.
Pediatric Use	Use is not established in children and adolescents, and a definite dosage recommendation cannot be given.
Older Adults	Not recommended for use in patients over mathbf70 years due to the likelihood of age-related renal function decline.
Pregnancy/Lactation	Contraindicated during pregnancy and contraindicated while breastfeeding.

---

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations:

• Patients with Severe Renal Impairment (creatinine clearance < 60 mL/min or serum creatinine > 135 mu mol/L), including dialysis patients. This is a major restriction specific to the 400 mg sustained-release dose.
• Patients with significant hepatic disease, Primary Biliary Cirrhosis, or pre-existing gallbladder disease.
• Patients with hypersensitivity to bezafibrate or any other fibrates, or a history of photoallergic reactions to fibrates.
• Combination therapy with statins is contraindicated if the patient has predisposing factors for muscle disease (myopathy), such as existing renal impairment or hormonal imbalances.

Interactions with other medicines and products

This section describes documented interaction patterns for Bezastad retard, as stated in official government regulatory documents.

---

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) that pose a risk of liver toxicity is formally restricted or contraindicated. The combination with HMG-CoA Reductase Inhibitors (Statins) is contraindicated when predisposing factors for myopathy (additive risk of muscle toxicity) are present. Crucially, renal impairment (kidney function impairment) is an example of a population-specific condition that officially makes the Statins combination prohibited.

---

Pharmacodynamic and Exposure Interactions

The medication can lead to a pharmacodynamic potentiation of other drugs. For instance, the effect of Vitamin K Antagonists (e.g., Warfarin) may be enhanced, which requires careful dosage monitoring. Similarly, co-administration with Antidiabetic Medications (e.g., Sulfonylureas, Insulin) can result in potentiation of the hypoglycemic effect. Separately, the concurrent use of Cyclosporine may lead to impairment of renal function and a corresponding increase in serum creatinine level, signifying altered bezafibrate clearance and higher drug exposure. An additive risk of myopathy is also documented when bezafibrate is combined with Colchicine.

---

Timing and Substance Requirements

To avoid impaired absorption, regulatory labeling mandates an interval of at least 2 hours between the intake of the tablet and Anion-Exchange Resins (e.g., Colestyramine). The rate and degree of absorption of the sustained-release formulation is only slightly reduced in the presence of food. Additionally, official prescribing information notes that alcohol intake should be limited.

Nuclear Receptor Modulation: The Genetic Switch

The mechanism of Bezastad retard begins at the molecular level as an agonist for the Peroxisome Proliferator-Activated Receptors ( PPARs), primarily PPARalpha. The drug activates these nuclear receptors, which function as transcriptional regulators, modulating the expression of genes responsible for lipid handling. This action establishes a sustained, 24-hour re-programming of metabolic enzymes and signaling proteins. The maintenance of chronic signaling is a function facilitated by the sustained-release (retard) formulation.

---

Enhanced Catabolism and Lipid Clearance

The PPARalpha-mediated gene modulation leads to a dual effect that accelerates the rate of lipid catabolism. It causes the upregulation of Lipoprotein Lipase ( LPL), the primary enzyme for hydrolyzing fats in the circulation, while simultaneously suppressing the inhibitory protein Apolipoprotein C-III ( ApoC-III). This coordinated action increases the systemic catabolism (breakdown) of triglyceride-rich lipoproteins, leading to their accelerated removal from the bloodstream and increases the synthesis of ApoA-I/ApoA-II (HDL components).

---

Reducing Hepatic Lipoprotein Synthesis

Complementing the enhanced clearance, the mechanism also addresses the supply of new circulating fats. By promoting the beta-oxidation of fatty acids in the liver and suppressing the synthesis pathway ( SREBP-1c), the drug diverts fat away from production. This reduces the amount of Very Low-Density Lipoprotein ( VLDL) the liver secretes, thereby reducing the overall concentration of triglycerides available in the circulation.

Instruction Map: How to use Bezastad retard — Administration Guidelines

---

Administration Scope

Instruction Entity	Administration Parameter
Route of administration	Oral administration only.
Dosing schedule	The standard adult regimen is 400 mg of bezafibrate, administered once daily.
Timing in relation to meals	The tablet should be taken with or immediately after a meal and swallowed with a sufficient volume of fluid.
Preparation requirements	The tablet must be swallowed whole and must not be crushed, chewed, or divided, as this would compromise the sustained-release mechanism.
Age-group administration rules	The standard adult dosing applies. The dosage may need careful adjustment, and the sustained-release form is often inappropriate for elderly patients whose kidney function is physiologically reduced.
Missed-dose rules	If a scheduled dose is missed, patients should take the next dose at the usual time; doubling the dose to compensate is not recommended.
Special procedural conditions	For concomitant use with bile acid sequestrants (e.g., cholestyramine), a time separation of at least 2 hours is required between the administration of the two medications.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily (once a day).
Basis of formulation	Standards for sustained-release bezafibrate.
Use-context constraints	The 400 mg retard form is strictly contraindicated if renal function is impaired (Creatinine Clearance < 60 mL/min or Serum Creatinine > 1.5 mg/dL). In such cases, the protocol involves a switch to the standard 200 mg formulation for appropriate dosing. Treatment continuation is generally evaluated after three months.

---

Resulting Procedural Structure

Step sequence:

• Take one 400 mg tablet once daily.
• Swallow the tablet whole (do not crush or chew).
• Administer the dose with or after a meal using sufficient fluid.

Connection to the overall use protocol (2–4 sentences): The instructions define the regimen as a single, daily oral dose that relies on proper tablet integrity and mealtime administration to maintain the extended release of the active ingredient. This standardized protocol sets clear, procedural constraints on concurrent medications and includes mandatory formulation restrictions based on kidney function to ensure appropriate long-term administration. The usage is governed by these established requirements.

Evidence for use in Primary and Mixed Dyslipidemias

Research into bezafibrate primarily relies on Randomized Controlled Trials (RCTs) designed to evaluate the medicine's effect on fundamental lipid biomarkers. Studies reported measurable changes in these biomarkers, specifically patterns of concentration shifts for triglycerides and Very Low-Density Lipoprotein (VLDL) in the direction of lower measurements, when compared to placebo groups. Research also described High-Density Lipoprotein Cholesterol (HDL-C) patterns that differed from control groups during these short-term studies. However, the majority of these initial efficacy studies focused on these surrogate markers (blood levels) over a short period, and long-term health outcomes are not well characterized by this evidence.

Evidence for use in High-Risk Cardiovascular Patients

Large-scale, long-term RCTs tracked serious clinical endpoints, including the rate of fatal and non-fatal myocardial infarction (heart attack) in patients with established Coronary Artery Disease (CAD). The main outcome evaluated across the entire study population of the largest clinical trial did not show a pattern distinct from the control group outcome. However, findings indicate that when researchers conducted specialized analyses on specific subgroups—particularly patients who had notably high triglyceride levels or features of the Metabolic Syndrome—these groups described patterns in event rates. Research also examined the relationship between bezafibrate use and the progression of atherosclerosis (hardening of the arteries).

Long-term Follow-up and Research Uncertainty

Extended long-term observational follow-up on initial trial cohorts was studied for all-cause mortality over periods extending up to 20 years. These analyses, which often involved post-hoc data, describe patterns in long-term survival. Certainty remains low for the broad population due to the mixed nature of the main trial finding. Data for certain groups, such as women, remain insufficient, and evidence quality varies across studies when compared to the original controlled phase. Comparative evidence against newer treatments is lacking in some areas.

Key Studies & References

1. Fibrates for primary prevention of cardiovascular disease events (Cochrane Review)

Common questions about Bezastad retard (FAQ)

---

Q: Is Bezastad retard the same type of medicine as [similar sounding drug name]?

Bezastad retard contains the active ingredient bezafibrate. According to official regulatory classifications, this medication belongs to the fibrate class of drugs. This classification describes its role in modulating blood fat levels, which is a key characteristic of medicines in this category.

---

Q: Do I need to change my diet while using Bezastad retard?

Official information indicates that this medication is generally considered an addition to other therapeutic measures, including diet. Regulatory documents describe that initial management of lipid imbalances (dyslipidemia) often involves dietary adjustments, and this medication is intended to be used alongside such measures.

---

Q: Can Bezastad retard cause long-term side effects?

Official regulatory documents classify certain severe adverse reactions, such as rhabdomyolysis (severe muscle breakdown) and hepatotoxicity (liver damage), as rare or very rare events. Due to these potential concerns, the official labeling mandates periodic monitoring of specific blood levels, such as liver function and CPK, over the course of treatment.

---

Q: Does Bezastad retard make you tired or dizzy?

Dizziness is documented in official adverse reaction profiles as a less common or common side effect associated with this medication. The possibility of experiencing such a side effect is noted in the regulatory documents for patient awareness.

---

Q: What is the risk of addiction or dependence with Bezastad retard?

Bezastad retard is classified as a fibrate (a lipid-lowering agent) by regulatory bodies. It is not listed as a controlled substance or an opioid in official regulatory drug schedules, which classify drugs based on their potential for misuse or dependence.

---

Q: Can Bezastad retard affect my ability to drive?

Official regulatory text advises that because bezafibrate has been shown to cause dizziness, it is considered to have a minor to moderate effect on a person’s ability to drive or operate machinery. This warning is included in the official product information.

---

Q: Is Bezastad retard safe for people over 65?

Regulatory labeling addresses use in older adults, stating that the sustained-release form is often not recommended for patients over the age of 70 years. This restriction is based on the likelihood of age-related changes in kidney function, which is a major constraint specific to the sustained-release formulation.

---

Q: Is Bezastad retard safe for use in children?

According to official regulatory information, the use of Bezastad retard is not established in children and adolescents. Due to the lack of evidence in these age groups, official documents state that a definite dosage recommendation cannot be given.

---

Q: What if I experience a rare side effect mentioned in the official document?

If a serious adverse event, such as rhabdomyolysis or liver damage, is suspected, regulatory labeling indicates that the treatment must be discontinued. Official documents describe that seeking medical advice is required when any serious reaction listed in the regulatory information is suspected.

---

Q: Is it possible to develop a tolerance to Bezastad retard?

The effectiveness of the drug over long periods has been a subject of research. The official summary of long-term trial findings states that the level of certainty remains low for the broad population, based on mixed results from the main trials.

---

Q: Is Bezastad retard an opioid?

Bezastad retard is officially classified as a fibrate medicine, which is a type of lipid-lowering agent used to adjust blood fat levels. It is not scheduled or classified as an opioid substance by official drug regulatory agencies.

---

Q: What is the typical duration of action for one dose of Bezastad retard?

The 'retard' designation means the tablet is specifically manufactured as a sustained-release formulation. This engineering is intended to release the active ingredient slowly and continuously over a full 24-hour period following administration.

---

Q: Do studies suggest Bezastad retard loses effectiveness over time?

Long-term observational follow-up studies on initial trial groups have been conducted to look at the persistence of the drug's effects. The official summary of these long-term trial findings indicates that the level of certainty remains low for the broad population, given the mixed nature of the main trial results.

---

Q: Why might a doctor switch me from immediate-release Bezastad to Bezastad retard?

The decision for which formulation to use is strictly governed by regulatory guidelines, particularly regarding kidney function. Regulatory text explicitly mandates a switch to the standard formulation when kidney function is impaired, meaning the sustained-release form is reserved for patients with adequate renal function.

---

Q: What is the standard regulatory classification of Bezastad retard?

Bezastad retard is formally classified as a prescription-only pharmaceutical preparation. It belongs to the fibrate class and is officially categorized as a lipid-lowering agent.

---

Q: How long is the total treatment period typically described in research for Bezastad retard?

Research studies have included long follow-up periods for patients. For example, long-term randomized controlled trials have tracked primary cardiovascular events for periods extending beyond six years, with follow-up on mortality data extending up to eight years.

Official Storage and Disposal Requirements

Official regulatory documentation mandates specific conditions for storing and disposing of Bezastad retard (bezafibrate sustained-release tablets) to maintain product stability and protect the environment.

Requirement Area	Labeled Regulatory Statement
Temperature	Store below 30 C (or 25 C); do not refrigerate or freeze.
Protection	Protect from moisture and keep the product in the original sealed container/blister pack.
Child Safety	Must be kept strictly out of the sight and reach of children.
Disposal	Do not dispose of unused or expired medicine via wastewater or general household waste.
Handling	Return unused or expired product to a pharmacist or local collection scheme for safe disposal.

These constraints define the required ambient environment and container integrity necessary for the product's labeled shelf-life. Environmental rules prohibit disposal through sewage or general trash.